Cue Biopharma, Inc. (CUE) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Cue Biopharma, Inc. (CUE) closed at USD 18.67 on 2026-10-15, a change of -9.8 % over the past year, with a market capitalization of USD 121.39M.

Cue Biopharma, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Cue Biopharma, Inc. key figures

Previous close

USD 18.67 (2026-10-15)

1-year change

-9.8 %

Market cap

USD 121.39M

Enterprise value

USD 107.05M

P/E ratio (trailing)

-0.57

P/E ratio (forward)

-34.81

EPS (trailing)

-29.59

EPS (forward)

-0.48

PEG ratio

n/a

Price to book

37.81

Revenue growth

166.7 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.70

Employees

29

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Cue Biopharma, Inc.

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Cue Biopharma, Inc. and compare it with other stocks.